Beractant Explained

Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids,fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.^[1] As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome.^[2] Survanta is manufactured by Abbvie.

Generic form

Beraksurf is generic form of Survanta (Beractant) which is manufacturing by Tekzima.

External links

• Web site: Beractant . U.S. National Library of Medicine . Drug Information Portal .

Notes and References

1. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, d'Agostino R . 6 . A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants . Pediatrics . 115 . 4 . 1018–29 . April 2005 . 15805380 . 10.1542/peds.2004-2183 . 40458323 .
2. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH . Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group . The Journal of Pediatrics . 132 . 1 . 40–7 . January 1998 . 9469998 . 10.1016/S0022-3476(98)70482-2 .